LEXICON PHARMACEUTICALS, INC. (LXRX) Return on equity 2016–2025
LEXICON PHARMACEUTICALS, INC. (LXRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-46.8%FY2025 · since FY2016: -78.5% → -46.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -46.8% | +90.5 pp |
| FY2024 | -137.3% | +52.9 pp |
| FY2023 | -190.2% | -103.2 pp |
| FY2022 | -87.0% | -9.8 pp |
| FY2021 | -77.3% | -39.8 pp |
| FY2020 | -37.5% | -148.6 pp |
| FY2019 | 111.1% | — |
| FY2017 | -180.2% | -101.7 pp |
| FY2016 | -78.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More LXRX financial trends
LXRX RevenueLXRX Net incomeLXRX Net marginLXRX Gross profitLXRX Gross marginLXRX Operating incomeLXRX Operating marginLXRX Operating cash flowLXRX Free cash flowLXRX Capital expendituresLXRX Stock buybacksLXRX Dividends paidLXRX Total assetsLXRX Total liabilitiesLXRX Shareholders’ equityLXRX overview →